ACCESS Newswire
20 Sep 2022, 11:19 GMT+10
GOTHENBURG, SE / ACCESSWIRE / September 20, 2022 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for their Liver Assist device, indicated for ex-vivo oxygenated machine perfusion for preservation of donor livers prior to transplantation. The FDA's Breakthrough Device Program is intended to expedite the development and prioritize the regulatory review of certain medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions than previous therapies.
The US is the largest liver transplant market globally with more than 8,600 livers transplanted in 2021[1]. In that year, the US performed more transplants than the next three largest markets combined (China, Brazil and Italy)[2]. The total US liver transplant market is expected to grow at an annual rate of 6 percent until 2030[3]. Additionally, the donation after circulatory death (DCD) segment of the market is expected to grow faster at approximately 15 percent per year in the same time frame[4]. An article published last year in The New England Journal of Medicine, shows that oxygenated hypothermic perfusion of DCD donor livers before transplantation has a significant positive impact on post-transplant clinical outcomes[5].
The overall goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to life-saving technologies by expediting their development, assessment, and review, through the FDA. As part of this program, the FDA will provide XVIVO with priority review and interactive communication ('sprint discussions') which provide a faster mechanism for communication with FDA compared to Pre-Sub meetings. This enables device development and review to move forward in an efficient manner and achieve a faster path to market access. The Breakthrough Devices Program not only expedites FDA review but also has the potential to facilitate Centers for Medicare and Medicaid Services (CMS) payment and positively affect future coverage benefits.
'In line with our strategy to become the market leader within abdominal transplantation we have taken a decision to commercialize our liver technology in the US. FDA's decision to grant a breakthrough designation indicates that the technology is innovative with the potential to be an improvement upon what is available on the market today. With more than 10 years of clinical experience, the Liver Assist is the most used device globally for machine perfusion of livers. As we believe in the extended life of organs we are very much looking forward to expanding this technology in the US after an FDA approval' says Dag Anderson, CEO of XVIVO.
September 20, 2022
Gothenburg
Dag Andersson, CEO
XVIVO Perfusion AB (publ)
[1] OPTN (Organ procurement and transplantation network - USA)
[2] GODT (Global observatory on organ donation and transplantation)
[3] XVIVO Market Intelligence & Forecast
[4] XVIVO Market Intelligence & Forecast
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa2031532
For further information, please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-mail: [email protected]
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: [email protected]
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
Attachments
XVIVO granted Breakthrough Device Designation from the FDA for the Liver Assist device
SOURCE: XVIVO Perfusion AB
Get a daily dose of Albuquerque Express news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Albuquerque Express.
More InformationMADRID, Spain: Liverpool footballer Diogo Jota and his younger brother, André Silva, have died in a car accident in Spain. Spanish...
LONDON, U.K.: An unrelenting heatwave sweeping across Europe has pushed early summer temperatures to historic highs, triggering deadly...
President Donald Trump's plans to build a space-based Golden Dome missile defense shield have drawn immediate criticism from China,...
NEW YORK CITY, New York: Paramount has agreed to pay US$16 million to settle a lawsuit brought by U.S. President Donald Trump over...
LONDON, U.K.: British Prime Minister Keir Starmer won a vote in Parliament this week to move ahead with changes to the country's welfare...
WASHINGTON, D.C.: President Donald Trump will meet Israeli Prime Minister Benjamin Netanyahu at the White House on Monday. President...
FRANKLIN, Tennessee: Hundreds of thousands of Nissan and Infiniti vehicles are being recalled across the United States due to a potential...
REDMOND, Washington: Microsoft is the latest tech giant to announce significant job cuts, as the financial strain of building next-generation...
LONDON UK - U.S. stock markets were closed on Friday for Independence Day. Global Forex Markets Wrap Up Friday with Greeback Comeback...
SANTA CLARA, California: Nvidia came within a whisker of making financial history on July 3, briefly surpassing Apple's all-time market...
SACRAMENTO, California: California's multibillion-dollar farms are facing a growing crisis—not from drought or pests, but from a sudden...
WASHINGTON, D.C.: President Donald Trump says the United States could soon reach a trade deal with India. He believes this deal would...